| First Author | Jaspers JE | Year | 2015 |
| Journal | Cancer Res | Volume | 75 |
| Issue | 4 | Pages | 732-41 |
| PubMed ID | 25511378 | Mgi Jnum | J:317861 |
| Mgi Id | MGI:6859049 | Doi | 10.1158/0008-5472.CAN-14-0839 |
| Citation | Jaspers JE, et al. (2015) BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance. Cancer Res 75(4):732-41 |
| abstractText | Pan- or multidrug resistance is a central problem in clinical oncology. Here, we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP inhibition. We found that multidrug resistance was strongly associated with an EMT-like sarcomatoid phenotype and high expression of the Abcb1b gene, which encodes the drug efflux transporter P-glycoprotein. Inhibition of P-glycoprotein could partly resensitize sarcomatoid tumors to the PARP inhibitor olaparib, docetaxel, and doxorubicin. We propose that multidrug resistance is a multifactorial process and that mouse models are useful to unravel this. |
